TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) was the recipient of some unusual options trading on Monday. Stock traders bought 13,544 put options on the stock. This represents an increase of approximately 170% compared to the average daily volume of 5,011 put options.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors have recently bought and sold shares of the stock. Pingora Partners LLC purchased a new stake in TG Therapeutics during the 4th quarter valued at about $27,000. DekaBank Deutsche Girozentrale bought a new position in TG Therapeutics during the 1st quarter valued at approximately $58,000. Lazard Asset Management LLC bought a new position in TG Therapeutics during the 1st quarter valued at approximately $91,000. nVerses Capital LLC increased its holdings in shares of TG Therapeutics by 34.9% in the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 1,500 shares in the last quarter. Finally, NBC Securities Inc. increased its holdings in shares of TG Therapeutics by 34.5% in the 4th quarter. NBC Securities Inc. now owns 9,401 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 2,409 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TGTX. HC Wainwright upped their price target on TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. LADENBURG THALM/SH SH increased their price objective on TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and set a $25.00 price objective on shares of TG Therapeutics in a report on Thursday, April 18th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $29.83.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock traded down $0.73 during trading on Monday, hitting $17.77. 1,520,643 shares of the stock traded hands, compared to its average volume of 3,603,516. The company has a quick ratio of 2.84, a current ratio of 3.62 and a debt-to-equity ratio of 0.63. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of 80.43 and a beta of 2.23. The firm’s fifty day moving average is $18.45 and its 200-day moving average is $16.51. TG Therapeutics has a 52 week low of $6.46 and a 52 week high of $23.12.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.